A controlled study on Risperidone and Chlorpromazine in the treatment of male schizophrenia

Objective: To research the efficacy and safety of risperidone and chlorpromazine in the treatment of schizophrenic patients. Methods: 120 male patients with schizophrenia by CCMD - 3 were randomly allocated to two groups treated with risperidone or chlorpromazine for 8 weeks. The Positive and Negative Syndrome Scale (PANSS) and Treatment Emergent Side effect Scale (TESS) were used to evaluate efficacy and adverse effect respectively.Results: The total scores of PANSS and the scores of every factors were significantly decreased. The efficacy rates of risperidone and chlorpromazine were 90.0% and 85.0% , without any significantly difference between two groups. Side effects in the risperidone group were fewer than in the chlorpromazine group, and especially the rates of extrapyramidal and anticholinergic side effects were lower.Conclusion: Risperidone has a similar total efficacy compared with chlorpromazine, but has fewer side effects.